<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; mounting</title>
	<atom:link href="http://www.tapanray.in/tag/mounting/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma And Healthcare: Mounting ‘Trust Deficit’ In Post Halcyon Days</title>
		<link>http://www.tapanray.in/pharma-and-healthcare-mounting-trust-deficit-in-post-halcyon-days/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-and-healthcare-mounting-trust-deficit-in-post-halcyon-days</link>
		<comments>http://www.tapanray.in/pharma-and-healthcare-mounting-trust-deficit-in-post-halcyon-days/#comments</comments>
		<pubDate>Mon, 01 Sep 2014 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[deficit]]></category>
		<category><![CDATA[disillusionment]]></category>
		<category><![CDATA[Doctored]]></category>
		<category><![CDATA[George Wilhelm Herman Emanuel Merck]]></category>
		<category><![CDATA[green]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Healthcheck]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Jauhar]]></category>
		<category><![CDATA[kickbacks]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Moody]]></category>
		<category><![CDATA[mounting]]></category>
		<category><![CDATA[NDTV]]></category>
		<category><![CDATA[operation]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shoots]]></category>
		<category><![CDATA[sting]]></category>
		<category><![CDATA[Sundeep]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[unbothered]]></category>
		<category><![CDATA[Vardhan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5795</guid>
		<description><![CDATA[Although a radical transformation in the field of medicine and path breaking advances of medical sciences are in progress, the healthcare system as whole, including the pharma industry, as voiced by many, is fast losing its human touch and values. &#8230; <a href="http://www.tapanray.in/pharma-and-healthcare-mounting-trust-deficit-in-post-halcyon-days/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-and-healthcare-mounting-trust-deficit-in-post-halcyon-days/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs -A raging scientific debate with mounting global commercial interest</title>
		<link>http://www.tapanray.in/biosimilar-drugs-a-raging-scientific-debate-with-mounting-global-commercial-interest/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-a-raging-scientific-debate-with-mounting-global-commercial-interest</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-a-raging-scientific-debate-with-mounting-global-commercial-interest/#comments</comments>
		<pubDate>Wed, 04 Mar 2009 13:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[mounting]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[raging]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[scientific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=953</guid>
		<description><![CDATA[On December 11, 2008, Reuters reported that two days after Merck &#38; Co. announced a major push into generic versions of biotechnology medicines, Eli Lilly &#38; Co. signaled similar aspirations. This report raised many eyebrows in the global pharmaceutical industry, &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-a-raging-scientific-debate-with-mounting-global-commercial-interest/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-a-raging-scientific-debate-with-mounting-global-commercial-interest/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
